Skip to main content

Table 2 Demographic and baseline characteristics

From: Pain and dyspnea control during awake fiberoptic bronchoscopy in critically ill patients: safety and efficacy of remifentanil target-controlled infusion

Age, mean ± SD, years

57.4 ± 17.4

Male, n (%)

29 (40)

BMI, mean ± SD, kg/m2

25 ± 6

SAPS2, mean ± SD

33 ± 16

Comorbidities, n (%)

 

 Active smoking

35 (49)

 COPD

23 (32)

 Other pulmonary disease

13 (18)

 Chronic heart disease

4 (6)

 Immunosuppression

30 (42)

Main cause of ICU admission, n (%)

 

 Respiratory failure

34 (48)

  Pneumonia

20 (28)

  Acute interstitial pneumonia

7 (10)

  Acute chest syndrome

4 (6)

  Other

3 (4)

 Hemoptysis

19 (26)

 Thoracic surgery/traumatism

11 (15)

 Abdominal surgery

1 (1)

 Extra-pulmonary sepsis

2 (3)

Other

5 (7)

Pre-bronchoscopic respiratory parameters

 

 SpO2, median [IQR], %

97 [94.8–99.2]

 RR, mean ± SD, per min

27 ± 9

 PaO2 < 60 mmHg, n (%)

17 (24)

 RR > 30 cycles per min, n (%)

34 (47)

Respiratory support, n (%)

  Oxygen therapy > 8L/min

30 (42)

  HFNC

15 (21)

  NIV

7 (10)

  Invasive mechanical ventilation

4 (6)

Pre-bronchoscopic hemodynamic parameters

 

 MAP, median [IQR], mmHg

93 [83–101]

 HR, mean ± SD, beat per min

99 ± 21

  1. BMI: body mass index, SAPS2: Simplified Acute Physiologic Score, COPD: chronic obstructive pulmonary disease, SpO2: oxygen saturation by pulse oximetry, RR: respiratory rate, PO2: arterial partial pressure of oxygen, HFNC: high-flow humidified oxygen therapy through nasal cannula, NIV: non-invasive ventilation, MAP: mean arterial pressure, HR: heart rate